Silo Pharma Gains Exclusive Global Rights for Alzheimer's Treatment

Silo Pharma, Inc. (Nasdaq: SILO) announced a significant advancement in its Alzheimer's drug development program by securing an exclusive global license for SPC-14. Silo Pharma, a developmental stage biopharmaceutical company, focuses on creating novel drug formulations and delivery systems for both traditional and psychedelic treatments. The company's CEO, Eric Weisblum, expressed optimism that SPC-14 could meet a substantial unmet medical need if approved, citing pre-clinical studies indicating the drug's potential for stress reduction and cognitive enhancement.

Silo Pharma aims to accelerate the development and approval process for SPC-14 by leveraging the FDA's 505(b)(2) pathway. This streamlined regulatory approach is designed to shorten clinical timelines and reduce overall drug development costs, offering a strategic advantage for the company.

In addition to SPC-14, Silo Pharma has also secured an exclusive license for SPC-15, its lead drug candidate. SPC-15 is an intranasal treatment aimed at addressing stress-induced affective disorders and post-traumatic stress disorder (PTSD). This strategic move aligns with the company's broader mission to tackle various underserved conditions, including psychiatric disorders, chronic pain, and central nervous system (CNS) diseases, through innovative therapeutic solutions.

The global market for Alzheimer's disease therapeutics is projected to surpass $30.8 billion by 2033, growing at a compound annual growth rate (CAGR) of 18.8% from 2024 to 2033. This robust market growth is primarily driven by the increasing prevalence of Alzheimer's disease among the expanding elderly population and significant advancements in neurological research.

SPC-14 represents a novel approach in Alzheimer's therapeutics, targeting the glutamate receptor NDMAR and the serotonin type 4 receptor 5HT4. Preclinical studies in small animals have demonstrated the drug's efficacy in mitigating stress-induced symptoms such as learned helplessness, perseverative behavior, and anxiety (measured by hyponeophagia).

Silo Pharma's portfolio also includes SP-26, a time-release ketamine-loaded implant designed for fibromyalgia and chronic pain management. Alongside SPC-14 and SPC-15, the company is developing SPU-16, a CNS-homing peptide targeting multiple sclerosis (MS). These research and development initiatives are carried out through collaborations with universities and independent laboratories, reflecting Silo Pharma's commitment to advancing medical science and improving patient outcomes.

Silo Pharma Inc. is dedicated to developing therapies targeting stress-induced psychiatric disorders, chronic pain conditions, and CNS diseases. The company's innovative approach includes both traditional and psychedelic treatments, formulated into novel drug delivery systems. With its strategic licensing agreements and robust pipeline, Silo Pharma is poised to make significant contributions to the medical field, particularly in areas with high unmet needs.

As Silo Pharma continues to advance its therapeutic programs, the company remains focused on leveraging scientific research and strategic collaborations to bring innovative treatments to market. With the potential approval of SPC-14 and other pipeline drugs, Silo Pharma aims to offer new hope and improved quality of life for patients and their families battling debilitating conditions like Alzheimer's disease and PTSD.